Guggenheim Securities continues to provide healthcare clients with independent insight and expertise across the biopharma, medical devices, and healthcare services sectors. Our full-service firm includes a leading healthcare investment banking franchise, trusted as a long-term, strategic advisor, as well as capital markets solutions and a research department that performs deep primary research and generates actionable ideas.
LinkedIn: INI Conference
Guggenheim Securities, LLC would like to thank the participants and attendees of the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, hosted by the firm's healthcare equity research analysts.
Healthcare Equities Sales Specialist Whitney Wolfe interviews Head of Equities Stefano Natella to discuss insights and highlights from “The Century Project,” a series of reports that analyzes health factors influencing longevity and healthspan.
Healthcare Equity Sales Specialist Whitney Wolfe interviews Senior Managing Director Punit Mehta, Healthcare Investment Banking, to discuss his outlook for M&A across the healthcare industry.
Global Biopharmaceutical and Biotechnology Equity Research Analyst Vamil Divan, MD, MBA spoke with Peter Loftus of The Wall Street Journal about the effects of the recent business revamp by one of the world's largest healthcare companies.
LinkedIn: Ryan Lindquist
Guggenheim Securities, LLC announced today that Ryan Lindquist has joined the firm as a Senior Managing Director in its Healthcare Investment Banking practice, where he will focus on diagnostics and life science tools.
Head of Equities Stefano Natella and Global Biopharmaceuticals Equity Research Analyst Seamus Fernandez spoke with Michelle Fox at CNBC about the impacts of sleep deprivation and the development of sleep management drugs.
LinkedIn: Palette Life Sciences
Guggenheim Securities, LLC congratulates Palette Life Sciences in connection with its $600 million (plus up to $50 million in commercial milestones) sale to Teleflex. Guggenheim served as the exclusive financial advisor to Palette.
LinkedIn: Evan Wang
Evan Wang, Healthcare Equity Research Analyst covering Global Biopharmaceuticals and Biotechnology, recently increased Guggenheim Securities' Healthcare Research footprint by expanding coverage in the infectious disease and liver sectors.
Guggenheim Securities, LLC, congratulates Zoetis in connection with the sale of Pumpkin to JAB HOLDING COMPANY LLC.
LinkedIn: Guggenheim Securities
Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks Radiopharmaceuticals Day.
Senior Managing Director Jennie Xue, Medical Devices Investment Banking, participated in a panel at #InnovationDublin23, to provide her perspective on the current state of the medical devices M&A environment.
LinkedIn: Rare Disease Days
Guggenheim would like to thank the participants and attendees of the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days.
LinkedIn: Healthcare Research
Vamil Divan, MD, MBA, Healthcare Equity Research Analyst covering the Global Biopharmaceutical and Biotechnology sectors, expanded Guggenheim Securities’ Healthcare Research footprint in late February by launching coverage on nine healthcare stocks.
Senior Managing Directors Punit Mehta and David Blais shared their views on the M&A outlook in healthcare with Michelle Davis from Bloomberg News.
LinkedIn: Summit Health
Guggenheim Securities, LLC congratulates Summit Health-CityMD, a portfolio company of Warburg Pincus LLC, in connection with its definitive agreement to be acquired by VillageMD, an affiliate of Walgreens Boots Alliance. Guggenheim served as a financial advisor to Summit Health-CityMD on the transaction.
LinkedIn: CNBC Closing Bell: Overtime
Biopharmaceutical Analyst Seamus Fernandez provides insight on CNBC Closing Bell: Overtime into his recent report on MRK.
LinkedIn: Immunology & Neurology Conference
Guggenheim would like to thank the presenters and attendees of the Immunology and Neurology Conference.
LinkedIn: Therapeutics Conference
Guggenheim would like to thank the participants and attendees of the Therapeutics Conference.
LinkedIn: I&I Spotlight Series
Guggenheim would like to thank the participants and attendees of the I&I Spotlight Series on Treg-based Therapies.
LinkedIn: Radiopharmaceutical Day
Guggenheim would like to thank the participants and attendees of Radiopharmaceutical Day.
LinkedIn: Synthetic Lethality Day
Guggenheim would like to thank the participants and attendees of Synthetic Lethality Day
LinkedIn: Genomic Medicines & Rare Disease Day
At Guggenheim’s 4th Annual Genomic Medicines and Rare Disease Day, we provided healthcare clients with access to industry leadership in the constantly evolving sector.
LinkedIn: Targeted Protein Degradation Day
Equity Research Analyst Michael Schmidt, who covers biotech, provides highlights from our Targeted Protein Degradation Day, a part of the Guggenheim Healthcare Talks series, on March 16.
LinkedIn: Biopharma Perspectives
At Guggenheim Securities, LLC we provide biopharmaceutical clients with independent insight and advice. As we survey 2022, we are sharing summaries of some of our most compelling thematic reports from the past year.
To access more information related to Healthcare at Guggenheim Securities, contact GSInfo@guggenheimpartners.com.
The information and materials provided herein (the “materials”) are provided for informational and educational purposes only and should not be considered a recommendation of any particular security, strategy or investment product, as investing advice of any kind, or as offering or providing any investment product or service, or as an offer or solicitation with respect to the purchase or sale of any investment by Guggenheim Securities, LLC or any of its affiliates (“Guggenheim”). The materials are not provided in an advisory or fiduciary capacity and may not be relied upon for or in connection with the making of investment decisions. The views expressed herein are solely those of the authors and may differ from the views of other officers, directors, employees or other representatives (as to any person or entity, its “Representatives”) of Guggenheim. The authors’ opinions are subject to change without notice. Guggenheim undertakes no obligation to provide additional information or any update to or correction of the information provided herein. Sources for the information contained herein are believed to be reliable, but the information is not guaranteed as to, and Guggenheim and its Representatives make no representation or warranty regarding, accuracy or completeness of any information contained herein or otherwise. Neither Guggenheim nor its Representatives shall be liable to any person in any way whatsoever for any losses, costs or claims for reliance on the materials. Guggenheim may have a business relationship with certain issuers mentioned herein, or may otherwise underwrite, hold a position, buy or sell as principal in the securities of any issuer mentioned. Guggenheim may have in the past provided, may currently be providing and may in the future seek to provide investment banking, financial advisory and other services to, and have other material relationships with, the issuers of securities, loans and other financial instruments referred to herein and their affiliates. With respect to any position Guggenheim may hold, Guggenheim may have interests different from or adverse to your interests. None of the materials provided may be reproduced or redistributed, in whole or in part, to any other person or published in whole or in part for any purpose absent the written consent of Guggenheim. By accessing or reviewing this website, you will be deemed to have acknowledged and agreed to the matters set forth above.
Copyright © 2023 by Guggenheim Securities, LLC, a FINRA registered broker-dealer. All rights reserved.